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Abstract 
Background: Artemisinin-based combination therapy is recommended as first-line anti-malarial treatment world-
wide. A combination of artemisinin with the long acting drug piperaquine has shown high efficacy and tolerability in 
patients with uncomplicated Plasmodium falciparum infections. The aim of this study was to characterize the popula-
tion pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers after two different dose sizes, 
formulations and in a combination with piperaquine. A secondary aim was to compare two different methods for the 
evaluation of bioequivalence of the formulations.
Methods: Fifteen subjects received four different dose regimens of a single dose of artemisinin as a conventional for-
mulation (160 and 500 mg) and as a micronized test formulation (160 mg alone and in combination with piperaquine 
phosphate, 360 mg) with a washout period of 3 weeks between each period (i.e. four-way cross-over). Venous plasma 
samples were collected frequently up to 12 h after dose in each period. Artemisinin was quantified in plasma using 
liquid chromatography coupled with tandem mass spectrometry. A nonlinear mixed-effects modelling approach was 
utilized to evaluate the population pharmacokinetic properties of the drug and to investigate the clinical impact of 
different formulations.
Results: The plasma concentration–time profiles for artemisinin were adequately described by a transit-absorption 
model with a one-compartment disposition, in all four sequences simultaneously. The mean oral clearance, volume 
of distribution and terminal elimination half-life was 417 L/h, 1210 L and 1.93 h, respectively. Influence of formulation, 
dose and possible interaction of piperaquine was evaluated as categorical covariates in full covariate approaches. No 
clinically significant differences between formulations were shown which was in accordance with the previous results 
using a non-compartmental bioequivalence approach.
Conclusions: This is the first population pharmacokinetic characterization of artemisinin in healthy volunteers. 
Increasing the dose resulted in a significant increase in the mean transit-time but the micronized formulation or con-
comitant piperaquine administration did not affect the pharmacokinetic properties of artemisinin. The results from 
the traditional bioequivalence evaluation were comparable with results obtained from mixed-effects modelling.
© 2016 Birgersson et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is still a major health problem and the emergence 
of multidrug-resistant Plasmodium falciparum parasites 
has further diminished the efficacy of available drugs [1]. 
Artemisinin-based combination therapy (ACT) is rec-
ommended by the World Health Organization as first-
line treatment of uncomplicated P. falciparum malaria. 
However, several reports indicate emerging artemisinin-
resistance in Southeast Asia characterized by increased 
parasite clearance times for artemisinin derivatives in 
patients with falciparum malaria [2–6]. A recent study 
has also identified a molecular marker, the K13-propeller 
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gene mutations, associated with artemisinin resistance 
[7]. Despite this emerging resistance, artemisinin and its 
derivatives are still effective in Africa and most regions of 
Southeast Asia. Treatment failure is commonly less than 
5 % at day 28 when administered in a combination with 
a longer acting anti-malarial drug in falciparum malaria 
[8–12]. However, alarming results have recently dem-
onstrated substantially decreased therapeutic efficacy of 
dihydroartemisinin–piperaquine in Western Cambodia 
[12, 13].
Artemisinin has previously been used as monotherapy 
(5-day treatment) with rapid parasite clearance, although 
with a high recrudescence rate due to the short half-life 
(1.4–2.6  h) [14–16]. Increasing the dose schedule to a 
7-day treatment did not substantially decrease recrudes-
cence [14]. Due to the pronounced metabolic auto-induc-
tion of artemisinin it has not been commonly used in 
artemisinin-based combinations. Studies in both patients 
and healthy volunteers have shown a decrease of 70–80 % 
to the exposure of artemisinin from the first day of dosing 
to the seventh day of dosing [17–19]. This reduction is a 
result of induction of several enzymes in the cytochrome 
P450 (CYP) family where CYP2B6 is the main metabo-
lizing enzyme of artemisinin with minor contribution of 
CYP2A6 and CYP3A4 [20–23]. Repeated oral adminis-
tration of artemisinin over 7 days has shown a two-fold 
increase in CYP2C19 and CYP2B6 activity at day 7 com-
pared to un-induced levels at day 1 [21, 22]. Significantly 
increased activity in CYP2C19, CYP3A and CYP1A2 has 
also been reported after repeated administration of arte-
misinin [20].
Piperaquine is a long-acting drug for co-administration 
in ACT, responsible for killing residual parasites and pre-
venting recrudescence. The fixed combination of dihy-
droartemisinin and piperaquine is well tolerated with 
high cure rates in areas with multidrug resistant P. falci-
parum [24–26].
Artemisinin and piperaquine, given as a combination, 
has shown excellent parasite clearance and fever clear-
ance times, comparable to that of dihydroartemisinin–
piperaquine and mefloquine–artesunate [27–29]. These 
three combinations all resulted in 100  % cure rates 
with no recrudescent malaria at day 28. However, there 
was a lower incidence of adverse events in the gastro-
intestinal tract after administration of artemisinin–
piperaquine as compared to after administration of 
dihydroartemisinin–piperaquine. Artemisinin–pipe-
raquine could also possibly be implemented as a sim-
plified dosing scheme of a 2-day therapy, compared to 
3 days in commonly used ACT. This was evaluated in 
the work by Thanh et  al. [30] where a 2-day therapy 
of artemisinin–piperaquine was compared to the con-
ventional 3-day treatment of artesunate–amodiaquine. 
Both treatments had similar effectiveness but the 
artesunate–amodiaquine combination had faster para-
site clearance times. However, this shorter treatment 
course raises concerns on parasite resistance develop-
ment and may not be a suitable alternative to the tradi-
tional 3-day treatment.
There are no studies presented on the pharmacokinet-
ics of intravenous administration of artemisinin, and no 
absolute oral bioavailability has been established. How-
ever, following intramuscular oil solution or supposito-
ries the relative oral bioavailability was approximately 
30 % [17, 31]. The low bioavailability of oral administra-
tion of artemisinin is probably due to low solubility and/
or high first pass metabolism [31, 32]. It is, therefore, 
desirable to increase the bioavailability of artemisinin. 
Attempts have been made to increase the oral bioavail-
ability by adding β- and γ-cyclodextrin complexes and 
thereby increasing artemisinin solubility [33]. Both the 
in  vivo rate and extent of artemisinin absorption was 
found to increase compared to the reference substance. 
Another alternative would be to re-formulate artemisinin 
as a micronized formulation to increase solubility and 
thereby bioavailability [34].
There have only been two previous studies success-
fully describing the population pharmacokinetics of 
artemisinin by Sidhu et  al. [35] and by Batty et  al. [36]. 
In the study by Sidhu et al. only a sparse sampling sched-
ule was applied in paediatric and adult patients with 
falciparum malaria, limiting its potential to adequately 
describe the pharmacokinetics and to identify relevant 
covariates. Batty et  al. developed a population pharma-
cokinetic model for three groups of paediatric patients. 
They concluded that the pharmacokinetic parameters of 
artemisinin in children are comparable to those in adults.
The objective of this study was to characterize the 
pharmacokinetic properties of artemisinin in healthy 
Vietnamese volunteers after different doses, formulations 
and in combination with piperaquine. The frequent sam-
pling schedule allowed for investigation of both absorp-
tion properties and possible biphasic disposition of 
artemisinin. A secondary aim was to compare the tradi-
tional model-independent bioequivalence methodology 
to a modelling-based approach.
Methods
Study design and ethical approval
The pharmacokinetic study was conducted at the 
Hospital for Tropical Diseases in Ho Chi Minh City 
(HTD-HCMC), Vietnam. Clinical details and non-com-
partmental analysis results are reported in full elsewhere 
[23]. The investigation was a single-centre, single-dose, 
open-label, randomized, four-sequence, cross-over 
study with a 3-week washout period (i.e. >5 artemisinin 
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half-lives) between occasions. The clinical trial proto-
col was approved by the internal Scientific and Ethical 
Committee of the HTD-HCMC and the Oxford Tropical 
Research Ethics Committee (OxTREC 019-06), Univer-
sity of Oxford, Oxford, UK. The volunteers were ran-
domly assigned to 1 of the 24 possible sequences for the 
4 treatments.
Treatment 1 (T1) comprised a single dose of two 
hard gelatin capsules [Trademark: Coni-Snap Cap-
sules (Capsugel [Thailand] Co., Ltd., Ayutthaya, Thai-
land)] (size 2), each containing 80  mg of micronized 
artemisinin powder; treatment 2 (T2) comprised a sin-
gle dose of two hard gelatin capsules, each containing 
80  mg of artemisinin powder (reference Vietnamese 
low-dose formulation); treatment 3 (T3) comprised a 
single dose of two hard gelatin capsules, each contain-
ing 250 mg of artemisinin powder (reference Vietnam-
ese dose-strength formulation); and treatment 4 (T4) 
comprised a single dose of two tablets, each containing 
80  mg of micronized artemisinin and 360  mg of pipe-
raquine phosphate.
Tolerability was assessed daily by the clinician during 
each study occasion (using an adverse-event report form) 
and at the follow-up visit 1  week after last study occa-
sion (using an adverse-event report form and laboratory 
assessment). Adverse events were accessed by using an 
open question about potential health problems during 
the study and followed up with a questionnaire if any 
health problems had occurred since the last consultation.
Study subjects
Study design and possible adverse drug effects were 
explained to all volunteers in their own language before 
initiation. Volunteers providing written informed consent 
were considered for enrollment. Clinical and laboratory 
screenings were performed at HTD-HCMC, Vietnam, 
and the results were evaluated before enrollment. Clini-
cal evaluation and laboratory assessment (full haema-
tology and biochemistry) were performed at follow-up 
1 week after the last study visit.
Exclusion criteria
Intake of any anti-malarial agent during the previous 
3 months, participation in an ongoing clinical drug study 
or within the last 3  months, involvement in the plan-
ning and/or conduct of the study, inability to comply 
with study procedure during the 10  weeks of participa-
tion, or intending to donate blood within 6 months after 
study start. Healthy volunteers, according to clinical and 
laboratory screening data, who fulfilled all of the inclu-
sion but none of the exclusion criteria were enrolled in 
the study.
Blood sampling
An intravenous indwelling cannula was introduced and 
maintained in the antecubital vein and kept for 12 h dur-
ing blood sample collection at each study visit. A blood 
volume of 0.5 mL was discarded before sample collection 
to avoid drug dilution effects. A 5 mL blood sample was 
drawn into lithium heparin tubes (Hong Thien My Medi-
cal Equipment Joint Stock Co., Ho Chi Minh City, Viet-
nam) before drug administration (pre-dose) and at the 
following times after drug administration (post-dose): 
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 12 h. The 
same time schedule was applied for all study visits. Saline 
solution (0.9 % sodium chloride, 2 mL) was used to flush 
the cannula after blood collection. Blood samples were 
immediately centrifuged at 3000×g for 10 min at 20  °C. 
Plasma were transferred to cryotubes within 10  min 
after centrifugation and stored at –70  °C. All samples 
were freighted on dry ice to the Department of Clinical 
Pharmacology at Mahidol–Oxford Tropical Medicine 
Research Unit (Bangkok, Thailand) where the plasma 
samples were analysed. The laboratory is a participant in 
the QA/QC proficiency testing programme supported 
by the Worldwide Antimalarial Resistance Network 
(WWARN) [37].
Drug analysis
Plasma concentrations of artemisinin were determined 
using a previously published LC–MS/MS method per-
formed on an API 5000 system (Applied Biosystems/
MDS SCIEX, Foster City, California) [38]. The limit of 
detection was 0.257 ng/mL with a linear range of quan-
tification of 1.03–762 ng/mL. Three independent quality-
control samples in plasma (2.89, 40.7, and 571  ng/mL) 
were prepared freshly and analysed in triplicates together 
with each batch of extracted plasma samples. The coef-
ficient of variation was below 5 % for all quality control 
samples.
Pharmacokinetic analysis
Artemisinin plasma concentrations were transformed 
into their natural logarithms and concentration–time 
data characterized using nonlinear mixed-effects mod-
elling in the NONMEM software (version 7.1.2; ICON 
Development Solutions, MD). Post-processing and auto-
mation were performed using Pearl-Speaks-NONMEM 
(PsN) (version 3.4.2) [39]; Pirana (2.4.0) [40], and Xpose 
(version 4.0) [41] package in R (version 2.13.1; The R 
Foundation for Statistical Computing). The first-order 
conditional estimation method with interactions was 
used throughout the modelling. Model discrimination 
was based on the objective function value (OFV; com-
puted by NONMEM as proportional to minus twice 
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the log likelihood of the data) and basic goodness-of-fit 
graphical analysis. A drop of 3.84 was considered signifi-
cant (p < 0.05) when comparing two nested models with 
one degree of freedom difference. Only 5  % of plasma 
samples (all within 30 min of dosing) were measured to 
be below the limit of quantification and therefore omitted 
in the analysis. One-, two- and three-compartment mod-
els with first-order elimination from the central compart-
ment were fitted to the plasma concentration–time data 
for artemisinin. Zero- and first-order absorption with 
and without an absorption lag-time was evaluated. A 
sequential absorption model (zero- and first-order) and a 
transit compartment model with 1–10 fixed transit com-
partments were also tried [42]. A relative bioavailability 
parameter, fixed to unity for the population, was evalu-
ated to allow inter-individual variability in the absorption 
of artemisinin.
Inter-individual variability was added exponentially as 
illustrated for clearance (Eq. 1).
where CL/Fi is the oral elimination clearance individu-
ally estimated for the ith patient and TV(CL/F) is the 
typical clearance value for the population. ηi,CL/F is the 
inter-individual variability, assumed to be normally dis-
tributed around zero and with a variance ω2. Inter-occa-
sion variability was evaluated on all parameters. The 
residual random variability was modeled with an additive 
error model on the log-transformed drug concentrations, 
being essentially equivalent to an exponential residual 
error on an arithmetic scale.
Covariates
After graphical evaluation relevant covariates were cho-
sen for the automatic covariate analysis. The continu-
ous covariates were age, weight, systolic blood pressure, 
diastolic blood pressure, heart rate and biochemical and 
haematological measurements (i.e. urea, glucose, cre-
atinine, total bilirubin, total protein, albumin, globulin, 
magnesium, ferritin, ALAT, ASAT, leukocytes, albumin/
globulin ratio, ferritin, erythrocytes, haemoglobin, haem-
atocrit, reticulocytes, thrombocytes, neutrophils, eosino-
phils, monocytes, basophils, lymphocytes). Smoking, 
formulation, dose size and possible drug–drug interac-
tions with concomitant piperaquine administration were 
investigated as categorical covariates.
Stepwise forward inclusion (p  <  0.05) were used for 
both continuous and categorical covariates followed by 
a stepwise backward exclusion (p < 0.01). The covariates 
were tested with a linear, hockey-stick, exponential and a 
power relationship. Bodyweight, centered on the median 
weight of the population, was also tested as an allomet-
ric function on clearance and volume parameters, where 
(1)CL/Fi = TV (CL/F) ∗ exp(ηi,CL/F )
clearance were scaled to mass to a power of 0.75 and 
where the volume was scaled to mass to the power of one 
[43–45].
Formulation effect, dose effect and possible drug–drug 
interactions with concomitant piperaquine administra-
tion were also investigated in the final pharmacokinetic 
model using a full covariate approach i.e. the covariate of 
interest was added as a categorical covariate on all esti-
mated fixed effects simultaneously. Formulation effect 
and dose effect were added to mean transit time and 
relative bioavailability while the drug–drug interaction 
with concomitant piperaquine was added to mean transit 
time, clearance and volume of distribution. These three 
covariate models were bootstrapped (n  =  500) and the 
90  % confidence interval of the covariate effects calcu-
lated to investigate the impact of each covariate on the 
pharmacokinetic properties of artemisinin. A covariate 
related change in the parameter estimate of more than 
20 % was assumed to be of clinical relevance.
Model evaluation
Basic goodness-of-fit characteristics were evaluated by 
plotting observed drug concentrations against individu-
ally predicted and population predicted drug concentra-
tions and by plotting conditionally weighted residuals 
against population predicted drug concentrations and 
time [46]. Eta and epsilon shrinkage were calculated to 
evaluate the reliability of the goodness-of-fit diagnostics 
[47]. Visual predictive checks were performed using 2000 
simulations at each concentration time point (protocol 
time points were used for binning). Bootstrap diagnostics 
(1000 re-sampled datasets stratified on formulation) were 
performed for the final model to obtain standard errors 
for parameter estimates and non-parametric confidence 
intervals around these parameters.
Simulations
Mean concentration–time profiles for healthy volun-
teers (present study), adult patients [35] and paediatric 
patients [36] were simulated in the software Berkeley 
Madonna [48]. Pharmacokinetic parameters were imple-
mented as described in literature and weighted-adjusted 
doses were implemented identical to that given to healthy 
volunteers.
Results
Fifteen healthy Vietnamese male volunteers aged 
19–41 years were enrolled and completed the study. Full 
demographic characteristics are given in Table 1. Seven 
hundred eighty-six (786) plasma samples of artemisinin 
were used in the pharmacokinetic analysis. Data from 
all four regimens were successfully modeled simulta-
neously with a nonlinear mixed-effects approach. The 
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pharmacokinetics of artemisinin was best characterized 
by a one-compartment disposition model with seven 
transit compartments in the absorption phase (Fig.  1). 
When the model was extended from one to two distri-
bution compartments, the OFV decreased significantly 
(ΔOFV = −16.9). However, this resulted in a substan-
tial increase in the peripheral volume of distribution 
(i.e. 66,900  L) leading to an unrealistic value for the 
terminal elimination half-life (127  h) and was not car-
ried forward. The addition of a third compartment did 
not improve the model fit significantly (p  >  0.05). A 
transit-compartment absorption model (n  =  7) was 
significantly better than all other absorption models 
tested (ΔOFV  =  −134). Inter-occasion variability on 
clearance and mean transit-time improved the model 
fit significantly (ΔOFV = −178). Inter-individual vari-
ability was retained on relative bioavailability with no 
additional benefit of implementing inter-individual 
variability on clearance, mean transit time or volume 
parameters. The population-derived pharmacokinetic 
estimates with relative standard errors are presented in 
Tables 2 and 3.   
Bodyweight, as an allometric function, did not improve 
the model fit and was not retained in the final model. 
Haemoglobin levels on mean transit-time and eosino-
phils counts on volume of distribution were both sig-
nificant in the stepwise covariate selection. However, 
the reduction in the inter-individual variability of these 
parameters and the residual error was minimal. Further-
more, no improvement of goodness of fit diagnostics 
was seen after the addition of these covariates. Conse-
quently, they were rejected in the final model. No other 
tested covariates were significant in the stepwise covari-
ate approach.
The final model showed satisfactory goodness-of-fit 
diagnostics (Fig. 2) with estimated epsilon shrinkage and 
eta shrinkages of <15  %. The final model showed good 
predictive performance, as illustrated by the visual pre-
dictive check, resulting in 4.22 % (95 % CI 2.69–7.80 %) 
and 4.22 % (95 % CI 2.81–7.67 %) of artemisinin obser-
vations below and above the simulated 90  % prediction 
interval, respectively (Fig. 3).
Table 1 Demographic data at  enrollment for  the 15 
healthy male Vietnamese subjects
SD standard deviation
Parameter Mean (SD) Median [range]
Age (years) 28.1 (8.5) 23 [19–41]
Weight (kg) 59.0 (9.3) 58 [43–80]
Height (cm) 166 (6.4) 167 [158–180]
Systolic blood pressure (mmHg) 115 (7.4) 110 [100–130]
Diastolic blood pressure (mmHg) 64.0 (6.3) 60 [60–80]












Fig. 1 Structural representation of the final model describing artemisinin population pharmacokinetics in healthy male Vietnamese subjects. kTR, 
absorption rate constant; CL, elimination clearance; VC, volume of distribution of the central compartment; F, relative oral bioavailability
Table 2 Parameter estimates of  the final model describing artemisinin population pharmacokinetics in  healthy male 
Vietnamese subjects
CL/F, apparent elimination clearance; V/F, apparent volume of distribution; Nr. trans comp, number of transit compartments in the absorption model; MTT, 
mean transit-time of the absorption phase; F, relative oral bioavailability; σ, additive residual error. RSE is the relative standard error calculated as 100 × standard 




 for inter-individual variability (IIV) and inter-occasion variability (IOV). 
95 % CI, 95 % confidence intervals calculated as the 2.5 and 97.5 percentiles of bootstrap estimates. Parameter estimates are based on population mean values from 
NONMEM, RSE % and CI values are based on 954 successful bootstrap runs (out of 1000)
Parameter Population estimate (RSE %) 95 % CI IIV/IOV* CV % (RSE %) 95 % CI
CL/F (L/h) 417 (9.32) 350-501 17.1* (34.3) 11.1-22.6
V/F (L) 1210 (9.02) 1030-1450 – –
Nr. trans comp 7 fix – – –
MTT (h) 0.787 (5.97) 0.702-0.891 53.9* (20.3) 41.6-66.9
F (%) 100 (fixed) – 34.3 (52.3) 17.3-50.5
σ (CV %) 51.6 (5.84) 44.9-58.1 – –
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In the full covariate model, mean transit-time increased 
by a median of 69.1 % with increasing dose size and there 
was a trend towards an increasing volume of distribu-
tion with increasing doses (160 vs 500 mg, Fig. 4b). None 
of the other parameters were influenced by artemisinin 
formulation (Fig. 4a), dose (Fig. 4b) or concomitant pipe-
raquine administration (Fig. 4c).
The simulations of mean concentration–time pro-
files for healthy volunteers, adult patients and paediatric 
patients are shown in Fig. 5.
Table 3 Secondary parameters of  the final model describing artemisinin population pharmacokinetics in  healthy male 
Vietnamese subjects
Secondary parameters estimated from the final model and values are presented as median [range]. Cmax is the maximum concentration and Tmax is the time to reach 
Cmax. t1/2 is the estimated terminal elimination half-life. AUC0–12 is the accumulated area under the concentration–time curve from time zero to 12 h after dose and 
AUC∞ is the accumulated area under the concentration–time curve from time zero extrapolated to infinity. Treatment 1 was administrated as 160 mg micronized 
artemisinin, treatment 2 was 160 mg of the reference formulation of artemisinin, treatment 3 was 500 mg of the reference formulation of artemisinin and treatment 4 
was 160 mg micronized artemisinin and 720 mg of piperaquine phosphate
Parameter Treatment 1 Treatment 2 Treatment 3 Treatment 4
Cmax (ng/mL) 111 [45.2–183] 96.7 [52.1–169] 244 [133–479] 144 [58–200]
Tmax (h) 1.41 [0.762–2.06] 1.09 [0.773–2.28] 1.72 [1.12–3.65] 0.992 [0.628–1.90]
t1/2 (h) 1.97 [1.64–3.37] 1.80 [1.46–3.20] 1.93 [1.71–2.43] 2.02 [1.64–2.42]
AUC0–12 (ng × h/mL) 461 [144–651] 342 [178–624] 956 [462–1973] 462 [189–744]


































































































Fig. 2 Goodness-of-fit diagnostics of the final model describing artemisinin population pharmacokinetics in healthy male Vietnamese subjects. 
Open circles represent observed concentrations versus population predicted concentrations (a) and individually predicted concentrations (b), and 
conditionally weighted residuals versus population predicted concentrations (c) and time after dose (d). Broken lines are locally weighted least-
squares regressions; solid lines represent the lines of identity. The concentrations are plotted on a logarithmic scale (base 10)
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Discussion
In the fight against malaria, WHO states that the neces-
sary tools are a combination of insecticide treated nets, 
indoor residual spraying, diagnostic tools and treatment 
with ACT [1]. However, the emerging resistance against 
the artemisinin compounds necessitates optimization of 
the current treatments to minimize the risk of develop-
ing drug resistance in areas where artemisinin resistance 
has not developed [2–4, 6, 49]. Artemisinin has not been 
used previously in ACT as a consequence of complicated 
pharmacokinetic properties due to the auto-induction of 
its own metabolizing CYP-enzymes [20–22]. However, 
in a short 2-day treatment the auto-induction will be less 
prominent [50] although with effectiveness comparable 
to a 3-day artesunate-mefloquine treatment [30].
In this work the pharmacokinetics of artemisinin was 
characterized using nonlinear mixed-effects modelling to 
estimate pharmacokinetic parameters and to evaluate the 
effect of different doses and a new micronized formula-
tion. Artemisinin population pharmacokinetics has been 
reported in two previous publications [35, 36]. While pre-
vious studies were conducted in patients with falciparum 
malaria this was the first time a population approach was 
implemented in healthy volunteers. The reference value 
obtained by this approach is of great importance in order 
to simulate appropriate doses and to evaluate potential 
interactions between concomitant drugs. Furthermore, 
it presents a baseline pharmacokinetic model in healthy 
volunteers, suitable for in silico clinical trial simulations 
in order to design informative future clinical trials.
The final model in the present study was a one-
compartment model, which adequately described the 
four sequences simultaneously. Adding a second com-
partment decreased the OFV significantly (p  <  0.05). 
However, this resulted in a decreased precision in the 
parameter estimates and an unreasonable estimate of 
the terminal elimination half-life (127  h) [17, 19, 35, 
36]. Therefore, a one-compartment model was retained. 
Sidhu et al. [35] reported on a study in 23 children and 
31 adults with uncomplicated falciparum malaria receiv-
ing a 5-day oral treatment of artemisinin. Two capil-
lary blood samples were collected after the first dose 
and one sample (from 30 % of the patients) after the last 
dose on day five. This study also concluded that a one-
compartment model described the data adequately. 
Batty et al. [36] investigated the exposure of artemisinin 
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Fig. 3 Prediction-corrected visual predictive check of the final model 
describing artemisinin population pharmacokinetics in healthy male 
Vietnamese subjects. Open circles represents the observations, the 
solid lines are 5th, 50th and 95th percentiles of the observations, and 
shaded areas represent the 95 % confidence interval of simulated 5th, 
50th and 95th percentiles
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Fig. 4 Box (25th and 75th percentile) and whisker (1.5 × interquartile range) plots of the full covariate models. The solid black zero-line represents no 
covariate effect (and the dotted black lines represent a covariate effect of ± 20 %). Formulation (a), dose (b) and the potential drug–drug interaction 
with piperaquine (c) were investigated as covariates. MTT is the mean transit-time, F is the relative oral bioavailability, V/F is the apparent volume of 
distribution and CL/F is the apparent elimination clearance. All covariates were added as categorical functions
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artemisinin–naphtoquine in three groups with differ-
ent doses. Rich data were collected for 48 h resulting in a 
two-compartment model as the best fit for the data. The 
implementation of this more complex model is possibly 
due to the longer sampling time compared to the present 
study.
Multiple absorption peaks and a large variability dur-
ing the absorption phase were observed in some sub-
jects in all treatment sequences which is in agreement 
with previously published data [35, 50]. In contrast to 
Sidhu et  al. and Batty et  al. a flexible transit compart-
ment absorption model was successfully applied for the 
absorption profile. In both previous studies a first-order 
absorption was found to be the best fit to the observed 
data, with a lag time in the paediatric study. The differ-
ent absorption models could be explained by more fre-
quent sampling in the absorption phase in this study. 
Overall, parameter estimates of the final model were 
estimated with a high precision in this study due to a 
highly informative sampling schedule with rich data in 
both the absorption and the elimination phase. Param-
eter estimates in this work in healthy volunteers were 
also in agreement with those reported in patients by 
Sidhu et  al. after taking into account the differences in 
bodyweight (allometrically scaled with a fixed exponent 
[CLstudy1 = CLstudy2 ∗
(
BWstudy1/BWstudy2
)0.75] for CL) 
[35, 44, 51].
The data in the present study was previously used 
in a non-compartmental analysis by Hien et  al. [23]. In 
that analysis, the two different formulations were con-
cluded to not fulfill the criteria for bioequivalence due 
to large variability, according to the FDA guidelines 
[52]. However, the clinical impact was considered to be 
negligible [23]. The full covariate population model-
ling approach used in the present study showed simi-
lar results with no absorption-related pharmacokinetic 
differences between the reference formulation and the 
micronized powder formulation. The effect of the com-
bination with piperaquine was also investigated using the 
same approach and showed no effect on the pharmacoki-
netics of artemisinin. A 3-week washout period between 
dosing occasions was incorporated in this study. This is 
enough to clear systemic artemisinin concentrations 
(i.e. >5 artemisinin half-lives). On the other hand, pipe-
raquine half-life is reported to be more than 25 days [53, 
54] which could be a possible limitation in the protocol 
and was therefore taken into consideration when evaluat-
ing the results. However, no apparent effect was found on 
artemisinin in actual co-administration with piperaquine, 
indicating that the low concentrations of piperaquine 
remaining after a 3-week washout period should not 
influence the pharmacokinetic properties of artemisinin. 
Furthermore, the risk of over predicting the influence 
of piperaquine on artemisinin pharmacokinetics (type 
I error) was assumed to be larger than the risk of not 
finding an effect (type II error) and therefore the limita-
tion in the study protocol was considered negligible. The 
study design with two different dose sizes for the conven-
tional formulation was due to earlier findings suggesting 
dose-dependent artemisinin pharmacokinetics [16, 55]. 
However, dose differences did not change the relative 
bioavailability although the mean transit-time increased 
substantially at higher doses in the present study. Possible 























Fig. 5 Simulated mean concentration–time profiles of healthy male Vietnamese volunteers (solid line, present study), adult patients (dashed line, 
[35]) and paediatric patients (dotted line, [36])
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solubility or elongated dissolution of the drug powder. It 
has previously been shown that artemisinin has a high 
permeability via passive diffusion, therefore, transporta-
tion across the intestinal membranes is not likely to be a 
rate-limiting step increasing mean transit-time [32].
The developed population pharmacokinetic model 
showed good predictive performance (Fig.  3) and is, 
therefore, suitable for population based simulations 
and clinical trial design. Mean concentration–time pro-
files for three groups, healthy volunteers, adult patients 
and paediatric patients, were simulated after receiv-
ing identical dosages (weight adjusted) of artemisinin 
as in the present study (Fig. 5). The time to reach maxi-
mum concentration occurs at almost the same time in 
all three groups, although adult patients have a lower 
maximum concentration compared to healthy volun-
teers and pediatric patients. The absorption models dif-
fer between healthy volunteers and patients, most likely 
due to sparse sampling in the absorption phase in the two 
patient studies. The exposure to artemisinin in children is 
unexpectedly higher than that in adult patients and simi-
lar to healthy volunteers. The higher exposure could be 
explained by a substantially higher dose in the study by 
Batty et al. [36] which could possibly result in a saturated 
elimination. This indicates that dose adjustment by allo-
metric scaling would be preferable to achieve comparable 
exposure as in healthy volunteers. This needs to be stud-
ied further for a firm paediatric dosing recommendation.
Conclusions
In conclusion, this is the first population pharmacokinetic 
characterization of artemisinin in healthy volunteers. 
The highly informative dense sampling resulted in a one-
compartment disposition model with a transit absorp-
tion model. Increasing the dose resulted in a significant 
increase in the mean transit-time but the micronized for-
mulation or concomitant piperaquine administration did 
not affect the pharmacokinetic properties of artemisinin. 
The results from the traditional model-independent bio-
equivalence approach were in agreement with results 
obtained from the modelling approach, based on the lim-
ited data from only one clinical study. The developed final 
model may be an important tool to investigate new dos-
ing regimens in silico and to be implemented in clinical 
trial simulations for informative design of future clinical 
trials.
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